BR112015026533A2 - tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina - Google Patents

tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina

Info

Publication number
BR112015026533A2
BR112015026533A2 BR112015026533A BR112015026533A BR112015026533A2 BR 112015026533 A2 BR112015026533 A2 BR 112015026533A2 BR 112015026533 A BR112015026533 A BR 112015026533A BR 112015026533 A BR112015026533 A BR 112015026533A BR 112015026533 A2 BR112015026533 A2 BR 112015026533A2
Authority
BR
Brazil
Prior art keywords
iciline
menthol
prevention
treatment
linalool
Prior art date
Application number
BR112015026533A
Other languages
English (en)
Inventor
Markram Henry
Le Coutre Johannes
Pezzoli Maurizio
Michlig Gonzalez Stéphanie
Camacho Susana
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112015026533A2 publication Critical patent/BR112015026533A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina". a presente invenção refere-se a composições para o tratamento ou a prevenção de desordens do autismo, e as composições contêm uma quantidade terapeuticamente eficaz de um composto selecionado do grupo que consiste em mentol, linalol, icilina e suas combinações. também são apresentados os métodos para o tratamento ou a prevenção de desordens do autismo, e os métodos incluem a administração de tais composições.
BR112015026533A 2013-05-24 2014-05-23 tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina BR112015026533A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827229P 2013-05-24 2013-05-24
PCT/EP2014/060642 WO2014187946A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of autism disorders using menthol, linalool and/or icilin

Publications (1)

Publication Number Publication Date
BR112015026533A2 true BR112015026533A2 (pt) 2017-07-25

Family

ID=50819729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026533A BR112015026533A2 (pt) 2013-05-24 2014-05-23 tratamento ou prevenção das desordens do autismo com o uso de mentol, linalol e/ou icilina

Country Status (10)

Country Link
US (2) US10369151B2 (pt)
EP (1) EP3003293B1 (pt)
JP (2) JP2016520589A (pt)
CN (3) CN110151766B (pt)
AU (1) AU2014270342C1 (pt)
BR (1) BR112015026533A2 (pt)
CA (1) CA2908348C (pt)
ES (1) ES2701324T3 (pt)
TR (1) TR201819348T4 (pt)
WO (1) WO2014187946A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3633699B2 (ja) * 1995-12-28 2005-03-30 株式会社資生堂 コエンドロ抽出物の使用
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6528076B2 (en) * 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
GB0229811D0 (en) 2002-12-20 2003-01-29 Unilever Plc Compound delivery systems
US20080213248A1 (en) * 2004-09-02 2008-09-04 University Of Florida Research Foundation, Inc. Methods and Systems for Treating Asthma and Other Respiratory Diseases
JP2006199662A (ja) * 2005-01-24 2006-08-03 Kodera Herb Garden:Kk 自閉症改善薬の製法
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
CN101677973A (zh) * 2007-02-06 2010-03-24 奥里金生物医学股份有限公司 用于抑制神经传导的包括萜烯化合物的组合物以及方法
EP2236042A1 (en) * 2009-03-30 2010-10-06 Nestec S.A. Fresh citrus juice and a method for preparing the same
JP5388759B2 (ja) * 2009-08-27 2014-01-15 美智士 谷 自閉症の改善薬、治療茶
CA2785056A1 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
CN102240280A (zh) * 2011-04-29 2011-11-16 李光武 一种经嗅觉通路脑靶向防治高血压及调节内脏功能芳香精油类的药物组合物
CN103717228A (zh) * 2011-05-26 2014-04-09 谷美智士 自闭症改进剂和自闭症改进茶
GB201110546D0 (en) * 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
CN102258751A (zh) 2011-07-21 2011-11-30 泰一和浦（北京）中医药研究院有限公司 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷

Also Published As

Publication number Publication date
US20160089370A1 (en) 2016-03-31
AU2014270342C1 (en) 2019-12-19
TR201819348T4 (tr) 2019-01-21
ES2701324T3 (es) 2019-02-21
CN105228600B (zh) 2019-08-30
US11241433B2 (en) 2022-02-08
CN115006399B (zh) 2024-04-05
US10369151B2 (en) 2019-08-06
AU2014270342A1 (en) 2015-10-08
US20190307748A1 (en) 2019-10-10
CN115006399A (zh) 2022-09-06
CN110151766B (zh) 2022-08-16
JP2019131601A (ja) 2019-08-08
JP2016520589A (ja) 2016-07-14
AU2014270342B2 (en) 2019-09-12
CA2908348A1 (en) 2014-11-27
EP3003293B1 (en) 2018-10-17
EP3003293A1 (en) 2016-04-13
CA2908348C (en) 2021-05-25
CN110151766A (zh) 2019-08-23
WO2014187946A1 (en) 2014-11-27
CN105228600A (zh) 2016-01-06

Similar Documents

Publication Publication Date Title
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112014026703A2 (pt) inibidores de dna-pk
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112015022538A2 (pt) terapia de indução de rituximab seguida por terapia de acetato de glatirâmero
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/045 (2006.01), A61K 31/513 (2006.01), A61P

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]